Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

125.50 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,742
Open 125.50
Bid (Size) 125.32 (100)
Ask (Size) 127.77 (500)
Prev. Close 125.50
Today's Range 125.50 - 125.50
52wk Range 104.46 - 157.29
Shares Outstanding 1,253,809,440
Dividend Yield 2.61%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial ↗
Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda Combination Ends 
Via Benzinga
News headline image
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
From Gilead Sciences, Inc.
Via Business Wire

Performance

YTD
+3.2%
+3.2%
1 Month
-6.0%
-6.0%
3 Month
-15.5%
-15.5%
6 Month
+5.1%
+5.1%
1 Year
+11.1%
+11.1%

More News

Read More
News headline image
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
From Merck & Co., Inc.
Via Business Wire
News headline image
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead ↗
Via MarketBeat
Gilead Sciences (NASDAQ:GILD) Screens as a Top Dividend Stock with Strong Profitability and Health ↗
Via Chartmill
News headline image
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands ↗
Via MarketBeat
News headline image
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH? ↗
Via The Motley Fool
Topics ETFs
News headline image
Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome ↗
Via Benzinga
News headline image
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗
Via Benzinga
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
Via The Motley Fool
News headline image
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
From Gilead Sciences, Inc.
Via Business Wire
News headline image
If You Invested $1000 In Gilead Sciences Stock 15 Years Ago, You Would Have This Much Today ↗
Via Benzinga
News headline image
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference ↗
Via MarketBeat
News headline image
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
From Gilead Sciences, Inc.
Via Business Wire
News headline image
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Compugen Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline ↗
Via MarketBeat
News headline image
3 Market-Beating Stocks to Research Further
Via StockStory
News headline image
Gilead Prices $3 Billion of Senior Unsecured Notes
From Gilead Sciences, Inc.
Via Business Wire

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 125.50
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 06/09/26 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 157.35B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 157B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.